GlassScriptPhysician profile
Christina Kendrick
NPI 1033144183
$12,598.64
in general payments reported to CMS, 2019-2025
32 companies · $2,774 in 2025
The $2,774 reported for 2025 was more than what 83% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,866 · 2020: $631 · 2021: $886 · 2022: $1,917 · 2023: $2,440 · 2024: $2,085 · 2025: $2,774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,192 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,191.87 |
| Education | $107.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,871.61 | 2019-2025 | |
| Lilly USA, LLC | $1,176.33 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $1,029.34 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $952.76 | 2019-2025 | Winlevi, Odomzo, Blu-U |
| Ucb, INC. | $798.95 | 2019-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $671.70 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $646.39 | 2019-2025 | |
| Pfizer INC. | $637.21 | 2019-2025 | |
| Leo Pharma INC. | $597.81 | 2019-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $575.87 | 2019-2025 | Dupixent, Libtayo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $348.91 | 2019-2024 | Siliq |
| Allergan, INC. | $334.23 | 2019-2022 | |
| Amgen INC. | $299.78 | 2020-2025 | Otezla, Otezla |
| Incyte Corporation | $207.19 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $164.78 | 2019-2025 | Nemluvio |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $162.52 | 2022-2024 | |
| Dermavant Sciences, INC. | $150.97 | 2022-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $138.42 | 2024-2025 | Zoryve |
| Celgene Corporation | $135.64 | 2019 | |
| Genentech USA, INC. | $122.17 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $102.95 | 2020-2025 | |
| Dusa Pharmaceuticals, INC. | $94.84 | 2019 | |
| Dermira, INC. | $76.51 | 2019-2020 | |
| Almirall LLC | $71.13 | 2021-2023 | Klisyri |
| Organon LLC | $59.18 | 2025 | |
| Kyowa Kirin, INC. | $41.55 | 2020-2023 | Poteligeo |
| Encore Dermatology INC. | $36.92 | 2019-2020 | |
| Krystal Biotech INC | $25.97 | 2025 | Vyjuvek |
| Biocon Biologics INC | $18.75 | 2025 | Yesintek |
| Verrica Pharmaceuticals INC. | $16.52 | 2024 | Ycanth |
| Prugen, INC. Pharmaceuticals | $16.06 | 2020 | |
| Sandoz INC. | $15.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Kendrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.